226 related articles for article (PubMed ID: 30839416)
1. Phase 2, Randomized, Dose-finding Studies of Omidenepag Isopropyl, a Selective EP2 Agonist, in Patients With Primary Open-angle Glaucoma or Ocular Hypertension.
Aihara M; Lu F; Kawata H; Iwata A; Liu K; Odani-Kawabata N; Shams NK
J Glaucoma; 2019 May; 28(5):375-385. PubMed ID: 30839416
[TBL] [Abstract][Full Text] [Related]
2. Intraocular pressure-lowering effect of omidenepag isopropyl in latanoprost non-/low-responder patients with primary open-angle glaucoma or ocular hypertension: the FUJI study.
Aihara M; Ropo A; Lu F; Kawata H; Iwata A; Odani-Kawabata N; Shams N
Jpn J Ophthalmol; 2020 Jul; 64(4):398-406. PubMed ID: 32572719
[TBL] [Abstract][Full Text] [Related]
3. Omidenepag Isopropyl Versus Latanoprost in Primary Open-Angle Glaucoma and Ocular Hypertension: The Phase 3 AYAME Study.
Aihara M; Lu F; Kawata H; Iwata A; Odani-Kawabata N; Shams NK
Am J Ophthalmol; 2020 Dec; 220():53-63. PubMed ID: 32533949
[TBL] [Abstract][Full Text] [Related]
4. A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6).
Olander KW; Sato MA; Abrams MA; Jerkins GW; Lu F; Dinh P; Odani-Kawabata N; Chabi A; Shams NK
J Glaucoma; 2021 Jun; 30(6):473-480. PubMed ID: 33813559
[TBL] [Abstract][Full Text] [Related]
5. A phase 2, randomized, dose-response trial of taprenepag isopropyl (PF-04217329) versus latanoprost 0.005% in open-angle glaucoma and ocular hypertension.
Schachar RA; Raber S; Courtney R; Zhang M
Curr Eye Res; 2011 Sep; 36(9):809-17. PubMed ID: 21851167
[TBL] [Abstract][Full Text] [Related]
6. Twelve-month efficacy and safety of omidenepag isopropyl, a selective EP2 agonist, in open-angle glaucoma and ocular hypertension: the RENGE study.
Aihara M; Lu F; Kawata H; Iwata A; Odani-Kawabata N
Jpn J Ophthalmol; 2021 Nov; 65(6):810-819. PubMed ID: 34495425
[TBL] [Abstract][Full Text] [Related]
7. Human experience and efficacy of omidenepag isopropyl (Eybelis®; Omlonti®): Discovery to approval of the novel non-prostaglandin EP2-receptor-selective agonist ocular hypotensive drug.
Sharif NA
Curr Opin Pharmacol; 2024 Feb; 74():102426. PubMed ID: 38168596
[TBL] [Abstract][Full Text] [Related]
8. Additive Intraocular Pressure-Lowering Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, Combined with Existing Antiglaucoma Agents in Conscious Ocular Normotensive Monkeys.
Fuwa M; Shimazaki A; Odani-Kawabata N; Kirihara T; Taniguchi T; Iwamura R; Yoneda K; Kato M; Morishima K; Shams NK
J Ocul Pharmacol Ther; 2021 May; 37(4):223-229. PubMed ID: 33600237
[No Abstract] [Full Text] [Related]
9. Omidenepag Isopropyl Versus Timolol in Patients With Glaucoma or Ocular Hypertension: Two Randomized Phase 3 Trials (SPECTRUM 4 and 3).
Bacharach J; Brubaker JW; Evans DG; Lu F; Odani-Kawabata N; Yamabe T; Wirta DL
Am J Ophthalmol; 2024 Jul; 263():23-34. PubMed ID: 38395329
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics, Safety, and Intraocular Pressure-Lowering Profile of Omidenepag Isopropyl, a Selective, Nonprostaglandin, Prostanoid EP2 Receptor Agonist, in Healthy Japanese and Caucasian Volunteers (Phase I Study).
Aihara M; Lu F; Kawata H; Tanaka Y; Yamamura K; Odani-Kawabata N; Shams NK
J Ocul Pharmacol Ther; 2019 Dec; 35(10):542-550. PubMed ID: 31674861
[No Abstract] [Full Text] [Related]
11. A 4-week, dose-ranging study comparing the efficacy, safety and tolerability of latanoprost 75, 100 and 125 μg/mL to latanoprost 50 μg/mL (xalatan) in the treatment of primary open-angle glaucoma and ocular hypertension.
Eveleth D; Starita C; Tressler C
BMC Ophthalmol; 2012 May; 12():9. PubMed ID: 22607109
[TBL] [Abstract][Full Text] [Related]
12. Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, on Aqueous Humor Dynamics in Laser-Induced Ocular Hypertensive Monkeys.
Fuwa M; Toris CB; Fan S; Taniguchi T; Ichikawa M; Odani-Kawabata N; Iwamura R; Yoneda K; Matsugi T; Shams NK; Zhang JZ
J Ocul Pharmacol Ther; 2018 Sep; 34(7):531-537. PubMed ID: 29989843
[TBL] [Abstract][Full Text] [Related]
13. Omidenepag Isopropyl in Latanoprost Low/Nonresponders With Primary Open Angle Glaucoma or Ocular Hypertension: A Phase 3, Nonrandomized, Two-Phase, Open-Label Study.
Panarelli JF; Bowden EC; Tepedino ME; Odani-Kawabata N; Pei Z; McLaurin EB; Ropo A
J Glaucoma; 2023 Dec; 32(12):999-1005. PubMed ID: 37853676
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Omidenepag Isopropyl 0.002% Ophthalmic Solution: A Retrospective Analysis of Real-World Data in Japan.
Miki A; Miyamoto E; Ishida N; Shii D; Hori K;
Adv Ther; 2022 May; 39(5):2085-2095. PubMed ID: 35287233
[TBL] [Abstract][Full Text] [Related]
15. Fixed combination of latanoprost and timolol vs individual components for primary open-angle glaucoma or ocular hypertension: a randomized, double-masked study.
Higginbotham EJ; Olander KW; Kim EE; Grunden JW; Kwok KK; Tressler CS;
Arch Ophthalmol; 2010 Feb; 128(2):165-72. PubMed ID: 20142538
[TBL] [Abstract][Full Text] [Related]
16. Once-Daily Netarsudil/Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure in the Randomized Phase 3 MERCURY-2 Study.
Walters TR; Ahmed IIK; Lewis RA; Usner DW; Lopez J; Kopczynski CC; Heah T;
Ophthalmol Glaucoma; 2019; 2(5):280-289. PubMed ID: 32672669
[TBL] [Abstract][Full Text] [Related]
17. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
Franks WA; Renard JP; Cunliffe IA; Rojanapongpun P
Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
[TBL] [Abstract][Full Text] [Related]
18. Phase 2b, Randomized, 3-Month, Dose-Finding Study of Sepetaprost in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: The ANGEL Study.
Wirta DL; Kuwayama Y; Lu F; Shao H; Odani-Kawabata N
J Ocul Pharmacol Ther; 2022 Apr; 38(3):240-251. PubMed ID: 35167779
[No Abstract] [Full Text] [Related]
19. Interim Results of Post-Marketing Observational Study of Omidenepag Isopropyl for Glaucoma and Ocular Hypertension in Japan.
Nakazawa T; Takahashi K; Kuwayama Y; Nomura A; Shimada F
Adv Ther; 2022 Mar; 39(3):1359-1374. PubMed ID: 35072890
[TBL] [Abstract][Full Text] [Related]
20. A 1-year study to compare the efficacy and safety of once-daily travoprost 0.004%/timolol 0.5% to once-daily latanoprost 0.005%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension.
Topouzis F; Melamed S; Danesh-Meyer H; Wells AP; Kozobolis V; Wieland H; Andrew R; Wells D
Eur J Ophthalmol; 2007; 17(2):183-90. PubMed ID: 17415690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
